There are no Transcripts on CLDA.
Feb. 22, 2011, 8:07 AMForest Laboratories (FRX) to acquire Clinical Data (CLDA) for $30/share in cash and another $6/share on milestones. The $1.2B deal is a 6.6% premium to the average share price since CLDA announced FDA approval of its major depressive disorder treatment Viibryd, which sent shares up more than 50%. (PR) | Comment!
Feb. 3, 2011, 9:10 AM
Jan. 24, 2011, 1:52 PMEight underperforming stocks with increasing put/call ratios, according to Kapitall: Clinical Data (CLDA), Home Inns & Hotels (HIHM), Supervalu (SVU), Volcom (VLCM), Orbitz (OWW), Ctrip.com (CTRP), Clearwire (CLWR), Taseko Mines (TGB). Contrarians may believe these stocks are set to rally based on a high number of open put positions relative to call positions. | Comment!
Jan. 24, 2011, 9:24 AM
CLDA vs. ETF Alternatives
Other News & PR